Stada’s owners improve offer
Stada Arzneimittel’s controlling shareholders, Bain Capital and Cinven, have made an improved €81.83 (US$94.38) per share offer to minority shareholders as they seek to take full control of the German generics and OTC specialist. The offer is a tenth higher than the previous €74.40 per share bid that failed to attract holders of 35% of Stada shares not currently held by their Nidda Healthcare vehicle (Generics bulletin, 11 May 2018, page 6).
You may also be interested in...
Nidda Healthcare, the investment vehicle controlled by Bain Capital and Cinven, has decided on a share price for the final squeeze-out of Stada’s remaining minority shareholders.
The US agency has announced four more webinars aimed at labs and manufacturers that are (or have) developed diagnostic tests for the novel coronavirus.
USPTO appeals board rejects requests by Charlotte's Web marketer in June and the Natural Leaf brand owner in September for trademarks. Those decisions sustain USPTO policy that even though FDA allows sales of food, supplements and other non-drug products subject to its oversight that contain hemp-derived CBD, the products are unlawful and trademarking brands for them is prohibited.